Targeting FoxM1 effectively retards p53-null lymphoma and sarcoma.

Area of Science:

• Oncology
• Molecular Biology
• Cancer Genetics

Background:

• The transcription factor FOXM1 is a potential cancer therapy target.
• The role of FOXM1 in p53-mutated tumors, common in many cancers, remains largely unknown.

Purpose of the Study:

• To investigate the therapeutic efficacy of targeting FOXM1 in spontaneous tumors lacking functional p53.
• To evaluate both genetic ablation and pharmacological inhibition of FOXM1.

Main Methods:

• Utilized genetic deletion of the FoxM1 gene in p53-null mouse models.
• Employed an ARF-derived peptide inhibitor to block FOXM1 activity.
• Assessed tumor growth, apoptosis, and expression of FOXM1 target genes (survivin, Bmi1).

Main Results:

• Conditional deletion of FoxM1 significantly inhibited the growth of p53-null thymic lymphoma and sarcoma.
• FOXM1 inhibition led to apoptotic cell death in p53-null tumors.
• Reduced expression of key FOXM1 targets, survivin and Bmi1, was observed.
• A peptide inhibitor of FOXM1 induced apoptosis and strongly inhibited metastatic colonization of p53-null sarcoma and lymphoma.

Conclusions:

• FOXM1 is essential for the survival and proliferation of lymphoma and sarcoma cells with p53 mutations.
• Targeting FOXM1 represents a viable therapeutic strategy for sarcomas and lymphomas with p53 loss-of-function mutations.